Most Read Articles
Roshini Claire Anthony, 2 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 5 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Jairia Dela Cruz, 6 days ago
Male smokers under the age of 50 years are at risk of developing ischaemic stroke, and this risk increases with the number of cigarettes smoked daily, according to data from the Stroke Prevention in Young Men Study.
Yesterday
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Dual-chamber pacing with closed loop stimulation reduces syncope burden, time to first recurrence

06 Oct 2017

Dual-chamber pacing with closed loop stimulation (DDD-CLS), compared with sham pacing, lessens by sevenfold syncope burden and time to first recurrence, extending time to first syncope recurrence in patients with head-up tilt test-induced vasovagal syncope, a recent study has found.

Canadian and Spanish patients (aged ≥40 years) with high burden syncope (≥5 episodes, ≥2 episodes in the past year) and a cardioinhibitory head-up tilt test (bradycardia <40 beats/min for 10 sec or asystole >3 sec) were randomly assigned to either DDD-CLS pacing for 12 months followed by sham DDI mode pacing at 30 pulses/min for 12 months (group A) or sham DDI mode for 12 months followed by DDD-CLS pacing for 12 months (group B).

Cross-over of patients in both arms occurred after 12 months of follow-up or when a maximum of three syncopal episodes occurred within 1 month.

Overall, 46 patients completed the protocol (mean age 56.30 years; 47.8 percent men), with a mean of 12 (range 9 to 20) previous syncopal episodes. Of the patients, 72 percent (95 percent CI, 47 to 90 percent) in the DDD-CLS had ≥50-percent reduction in the number of syncopal episodes compared with 28 percent (9.7 to 53.5 percent) in the sham DDI mode (p=0.017).

Events occurred in four patients (8.7 percent) during DDD-CLS and in 21 (45.7 percent) during sham DDI (hazard ratio, 6.7; 2.3 to 19.8). There was significantly different Kaplan-Meier curve between groups in the time to first syncope (29.2 months; 15.3 to 29.2 vs 9.3 months; 6.21 to NA; p<0.016; odds ratio, 0.11; 0.03 to 0.37; p<0.0001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 5 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Jairia Dela Cruz, 6 days ago
Male smokers under the age of 50 years are at risk of developing ischaemic stroke, and this risk increases with the number of cigarettes smoked daily, according to data from the Stroke Prevention in Young Men Study.
Yesterday
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.